EQS-News: Alzchem Group AG continues growth trajectory in the first half of 2025 – forecast for the full year confirmed

Alzchem Group AG continues growth trajectory in the first half of 2025 – forecast for the full year confirmed

• EBITDA rises by 9% to EUR 56.5 million thanks to positive volume development in specialty chemicals
• Free cash flow remains clearly positive despite increased investments

Trostberg, July 30, 2025 – Alzchem Group AG, a globally active specialty chemicals company, continued its successful development in the first half of 2025, increasing key figures such as sales, EBITDA, and consolidated result. With sales of EUR 287.6 million, the Group slightly exceeded the previous year’s level of EUR 286.3 million. EBITDA increased by 9% from EUR 51.9 million to EUR 56.5 million, corresponding to an EBITDA margin of 19.6% (previous year: 18.1%). Consolidated net income rose by 14% from EUR 26.7 million to EUR 30.5 million. The financial position also continued to develop very positively in the first half of 2025. Operating cash flow increased significantly from EUR 63.8 million to EUR 71.2 million. This was mainly due to customer grants of EUR 51.0 million received for the expansion of production capacities for nitroguanidine. Despite the associated increase in the Group’s capital expenditure, free cash flow remained clearly positive at EUR 30.7 million (previous year: EUR 51.4 million).

The Specialty Chemicals segment once again proved to be the growth driver in the first half of 2025, increasing its sales by 9% from EUR 178.8 million to EUR 194.6 million. In particular, the encouraging development in the Human Nutrition business with continued strong demand for creatine “Made in Germany” and in the Custom Manufacturing business with a positive trend reversal compared to previous years led to an 18% increase in segment EBITDA from EUR 45.5 million to EUR 53.9 million. The EBITDA margin improved accordingly from 25.5% to 27.7%. In contrast, the downward trend in the Basics & Intermediates segment continued as expected in the months from January to June 2025. Sales fell by 14% from EUR 91.1 million to EUR 78.2 million, which was due, among other things, to the weak economic situation in the European and German steel industry and further increasing price pressure from Chinese suppliers. Segment EBITDA declined from EUR 4.9 million to EUR 1.3 million due to the weak economy in the metallurgy sector and higher electricity prices.

The expansion of production capacity for nitroguanidine in Germany is proceeding according to plan and remains on schedule and within budget. At the same time, the search for a site for an additional production facility in the US is continuing. As various sites have already been visited and evaluated, Alzchem is currently drawing up a long list, which is expected to be narrowed down for a decision in the second half of the year.

In view of the positive business development in the first half of the year, Alzchem confirms its forecast for the full year 2025: Among other things, organic sales growth of approximately 5% to around EUR 580 million and an increase in EBITDA of approximately 7% to around EUR 113 million are anticipated. The resulting EBITDA margin is expected to climb to approximately 19.5%.

Andreas Niedermaier, CEO of Alzchem Group AG, comments: “Our consistent focus on high-margin specialty chemicals continues to pay off despite the ongoing challenging conditions. The strong increase in sales and, above all, earnings in the Specialty Chemicals segment shows that our strategic focus on future-oriented, high-growth niche markets is having a lasting effect. The noticeable upturn in demand for highly specialized products despite a difficult overall industry environment is particularly encouraging – a clear signal of our high level of innovation and customer focus.”

The detailed half-year report 2025 is available for download on the website www.alzchem.com in the Investors/Publications section

About Alzchem

Alzchem is a leading international specialty chemicals company that provides sustainable solutions to global challenges such as climate change, population growth, defense, and increasing life expectancy. With its comprehensive product range, the company is often the market leader in profitable niche markets in diversified industries. It serves sectors such as human and animal nutrition and agriculture, helping to efficiently meet the growing demand for food. Its own pharmaceutical raw materials and creatine products also support healthy aging. Alzchem is also involved in renewable energies and fine chemicals, produces important raw materials for the defense industry, and guarantees a high level of independence and supply security through its “Made in Germany” production.

With around 1,700 employees at four locations in Germany, a plant in Sweden, and three sales companies in the US, China, and England, Alzchem generated sales of EUR 554.2 million and EBITDA of EUR 105.3 million in 2024.